Dendritic cell recruitment following xenografting of pig fetal mesencephalic cells into the rat brain.

Following transplantation into the rat brain, porcine neuroblasts differentiate and integrate host tissue, but due to their xenogeneic nature, these cells are generally rejected within several weeks. This rejection is accompanied by infiltration of the graft by macrophages and alphabetaT lymphocytes, but so far nothing is known about the potential role of dendritic cells (DCs) in this process. DCs are professional antigen presenting cells that have the unique ability to prime naive T cells, thereby initiating an antigen-directed immune response. Here, we provide evidence for DC recruitment following the transplantation of pig mesencephalic neural cells into the striatum of LEW.1A rats, as indicated by the high number of OX62+ cells in the rejecting graft and the absence of V65 staining. DCs were found as early as 3 and 8 days postimplantation together with ED1+ and OX42+ cells. This early recruitment, which is probably due to the surgical procedure, might be a critical step in the rejection process, enabling DCs to be loaded with xenoantigens. The number of intracerebral DCs subsequently decreased, being barely detectable in older non-infiltrated xenografts. However, DCs re-appeared as they were observed in grafts infiltrated by macrophages and T cells, a phenomenon that usually precedes graft rejection. Interestingly, we observed a tight correlation between the number of DCs and that of R7.3+ T cells infiltrating the graft. In addition, DCs were often found in close proximity to alphabetaT cells and most expressed MHCII. Taken together, these findings give credence to a role for infiltrating DCs in the mediation of T cell responses to intracerebral xenografting.

Long-lasting coexpression of nestin and glial fibrillary acidic protein in primary cultures of astroglial cells with a major participation of nestin(+)/GFAP(-) cells in cell proliferation.

Nestin, a currently used marker of neural stem cells, is transiently coexpressed with glial fibrillary acidic protein (GFAP) during development and is induced in reactive astrocytes following brain injury. Nestin expression has also been found in cultures of astroglial cells, but little is known about the fate and the mitotic activity of nestin-expressing cells in this in vitro model. The present study reveals a long-lasting expression of nestin in primary cultures of astroglial cells derived from the rat brain. Over 70% of the cells were nestin(+) at 12 weeks, with a large majority coexpressing the GFAP astrocytic marker. Time-course analyses supported a transition from a nestin(+)/GFAP(-) to a nestin(+)/GFAP(+) phenotype over time, which was further increased by cell cycle arrest. Interestingly, double staining with Ki67 revealed that over 90% of cycling cells were nestin(+) whereas only 28% were GFAP(+) in a population consisting of almost equivalent numbers of nestin(+) and GFAP(+) cells. These observations indicated that nestin(+)/GFAP(-) cells are actively engaged in mitotic activity, even after 2 weeks in vitro. Part of these cells might have retained properties of neural stem cells, insofar as 10% of cells in a primary culture of glial cells were able to generate neurospheres that gave rise to both neurons and astrocytes. Further studies will be necessary to characterize fully the proliferating cells in primary cultures of glial cells, but our present results reveal a major contribution of the nestin(+)/GFAP(-) cells to the increase in the number of astrocytes, even though nestin(+)/GFAP(+) cells proliferate also.

Short report: High prevalence of multidrug-resistant Plasmodium falciparum malaria in the French territory of Mayotte.

A drug-resistance survey was conducted in the French territory of Mayotte in the Comorian Islands in the Indian Ocean where malaria is endemic. A high prevalence of resistant Plasmodium falciparum parasites was observed, not only to chloroquine (88%) and pyrimethamine (99%), but more surprisingly to quinine (17%), mefloquine (9%), and amodiaquine (24%). This leaves few treatment alternatives other than artemisine-mefloquine combinations. However, despite notification to French Health authorities three years ago, inadequate treatment (chloroquine plus sulfadoxine-pyrimethamine) is still used in this locality. Thus, people still die of malaria in this remote territory of France.